Xilio Therapeutics Inc. (XLO)
Xilio Therapeutics Statistics
Share Statistics
Xilio Therapeutics has 45.76M shares outstanding. The number of shares has increased by 59.6% in one year.
| Shares Outstanding | 45.76M |
| Shares Change (YoY) | 59.6% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | 22.81% |
| Shares Floating | 19.01M |
| Failed to Deliver (FTD) Shares | 109 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 213.07K, so 0.48% of the outstanding shares have been sold short.
| Short Interest | 213.07K |
| Short % of Shares Out | 0.48% |
| Short % of Float | 1.08% |
| Short Ratio (days to cover) | 0.21 |
Valuation Ratios
The PE ratio is -0.2 and the forward PE ratio is -1.12. Xilio Therapeutics's PEG ratio is 0.02.
| PE Ratio | -0.2 |
| Forward PE | -1.12 |
| PS Ratio | 0 |
| Forward PS | 1.2 |
| PB Ratio | 0.41 |
| P/FCF Ratio | -218.83 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Xilio Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.02, with a Debt / Equity ratio of 0.31.
| Current Ratio | 3.02 |
| Quick Ratio | 3.02 |
| Debt / Equity | 0.31 |
| Total Debt / Capitalization | 23.73 |
| Cash Flow / Debt | -5.99 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.07% and return on capital (ROIC) is -163.89%.
| Return on Equity (ROE) | -2.07% |
| Return on Assets (ROA) | -1.25% |
| Return on Capital (ROIC) | -163.89% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.05M |
| Employee Count | 73 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 26.32% in the last 52 weeks. The beta is -0.26, so Xilio Therapeutics's price volatility has been lower than the market average.
| Beta | -0.26 |
| 52-Week Price Change | 26.32% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 0.95 |
| Relative Strength Index (RSI) | 48.23 |
| Average Volume (20 Days) | 4.07M |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.9M |
| Operating Income | -79.13M |
| Net Income | -76.4M |
| EBITDA | -73.8M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.78 |
Balance Sheet
The company has 44.7M in cash and 11.46M in debt, giving a net cash position of 33.25M.
| Cash & Cash Equivalents | 44.7M |
| Total Debt | 11.46M |
| Net Cash | 33.25M |
| Retained Earnings | -325.51M |
| Total Assets | 74.66M |
| Working Capital | 25.29M |
Cash Flow
In the last 12 months, operating cash flow was -68.62M and capital expenditures -486K, giving a free cash flow of -69.11K.
| Operating Cash Flow | -68.62M |
| Capital Expenditures | -486K |
| Free Cash Flow | -69.11K |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -305.49% |
| FCF Yield | -0.17% |
Analyst Forecast
The average price target for XLO is $4, which is 339.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 339.6% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -8.75 |
| Piotroski F-Score | 4 |